PHS
AXSM icon

PFM Health Sciences’s Axsome Therapeutics AXSM Stock Holding History

PFM Health Sciences’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-200,000
Closed -$14.4M – 74
2023
Q2 		$14.4M Buy
+200,000
New +$14.8M 0.56% 50
2023
Q1 		– Sell
-299,000
Closed -$23.1M – 81
2022
Q4 		$23.1M Buy
+299,000
New +$17.9M 0.83% 48

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PFM Health Sciences's AXSM Position: Q1 2026 in Review

PFM Health Sciences increased its Axsome Therapeutics (AXSM) stake by 5.1% in Q1 2026, buying an estimated $2.2M and bringing the position to 264,304 shares worth $44.7M. The position accounts for 4.07% of the portfolio, ranked #5.

PFM Health Sciences first reported a position in AXSM in Q2 2022 and has held it in 16 quarters since. The position peaked at $84.3M in Q4 2022. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • PFM Health Sciences held 264,304 shares of Axsome Therapeutics worth $44.7M as of Q1 2026.
  • PFM Health Sciences bought 12,742 Axsome Therapeutics shares in Q1 2026, an estimated $2.2M.
  • Axsome Therapeutics made up 4.07% of PFM Health Sciences's portfolio in Q1 2026, its #5 holding.
  • PFM Health Sciences first reported a position in Axsome Therapeutics in Q2 2022 and has held it in 16 quarters since.
  • PFM Health Sciences's Axsome Therapeutics position peaked at $84.3M in Q4 2022.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on PFM Health Sciences's 13F filing for Q1 2026, filed 15 May 2026.